Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Genelux Corporation
Genelux Corporation
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
M.D. Anderson Cancer Center
Corcept Therapeutics
Corcept Therapeutics
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Corcept Therapeutics
EpicentRx, Inc.
Mayo Clinic
Chinese PLA General Hospital
RenJi Hospital
OHSU Knight Cancer Institute
Corcept Therapeutics
AstraZeneca
Peking University Third Hospital
Celgene
University of Washington